Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Methotrexate transport and resistance

J A Moscow1

  • 1Department of Pediatrics, University of Kentucky Medical Center, Lexington 40536, USA.

Leukemia & Lymphoma
|August 26, 1998
PubMed
Summary

Methotrexate resistance in cancer cells is linked to reduced folate carrier (RFC) activity. Defects in the RFC1 gene are implicated, but other transporters may also contribute to drug resistance.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transporter gene expression in lactating and nonlactating human mammary epithelial cells using real-time reverse transcription-polymerase chain reaction.

The Journal of pharmacology and experimental therapeutics·2002
Same author

Down-regulation of reduced folate carrier gene (RFC1) expression after exposure to methotrexate in ZR-75-1 breast cancer cells.

Biochemical and biophysical research communications·2001
Same author

Interactions between cimetidine, nitrofurantoin, and probenecid active transport into rat milk.

The Journal of pharmacology and experimental therapeutics·2000
Same author

Langerhans cell histiocytosis after therapy for a malignant germ cell tumor of the central nervous system.

Journal of pediatric hematology/oncology·2000
Same author

Paclitaxel chemotherapy after autologous stem-cell transplantation and engraftment of hematopoietic cells transduced with a retrovirus containing the multidrug resistance complementary DNA (MDR1) in metastatic breast cancer patients.

Clinical cancer research : an official journal of the American Association for Cancer Research·1999
Same author

Engraftment of MDR1 and NeoR gene-transduced hematopoietic cells after breast cancer chemotherapy.

Blood·1999

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Methotrexate (MTX) is an antifolate drug used in cancer chemotherapy and immunosuppression.
  • Cellular sensitivity to MTX depends on its internalization, primarily via the reduced folate carrier (RFC).
  • Reduced RFC activity is a known mechanism of MTX resistance.

Purpose of the Study:

  • To investigate the role of RFC1 gene expression in MTX resistance.
  • To explore other potential folate transport mechanisms contributing to MTX resistance.

Main Methods:

  • Analysis of RFC1 gene expression in MTX-resistant cell lines.
  • Studies of MTX uptake in cancer cells.
  • Investigation of folate transport in physiological systems.

Main Results:

  • Defects in RFC1 gene expression were identified in transport-deficient, MTX-resistant cell lines.
  • RFC1 expression is crucial for transport-mediated antifolate drug resistance.
  • Evidence suggests other proteins, distinct from RFC1, also facilitate folate uptake.

Conclusions:

  • RFC1 plays a significant role in mediating cellular sensitivity to MTX.
  • The existence of additional RFC-like transporters implies complex mechanisms of antifolate drug resistance.
  • Further research is needed to identify and characterize these alternative folate transporters.

Related Experiment Videos